Translating Data: Post-BCMA Therapy

Sequencing BCMA Myeloma TherapiesПодробнее

BCMA Therapy & the Road to Remission in MyelomaПодробнее

Novel agents in the post-BCMA space in myelomaПодробнее

Efficacy and safety of elranatamab BCMA-CD3 bispecific antibody, in patients with RRMMПодробнее

Clinical translation of carfilzomib trial data for MM treatmentПодробнее

Betting on BCMA Therapy in Multiple MyelomaПодробнее

Hitting the BCMA Target in Multiple MyelomaПодробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

Treatment Advances in Myeloma: Expert Perspectives on Translating Clinical Data to PracticeПодробнее

Impact of prior BCMA-directed therapy on the efficacy of elranatamab in R/R multiple myelomaПодробнее

Innovative Therapy in Multiple Myeloma: Monoclonal Antibodies and BCMA and Non-BCMA OptionsПодробнее

Dr Ip on the Impact of BCMA Alternative Splicing in Lymphoma and Multiple MyelomaПодробнее

Multiple Myeloma: The Convergence of Novel Therapeutic Platforms, Cell Therapy, and ASCTПодробнее

BCMA: Predicting Outcomes and Monitoring MM and CLLПодробнее

Integrating BCMA-directed bispecifics and CAR-T into the myeloma treatment landscapeПодробнее

BCMA Antibodies and Cellular Therapies in RRMMПодробнее

Translating Data: The COMPASS StudyПодробнее

BCMA-Directed Therapy in Multiple Myeloma: Assessing the Clinical ImpactПодробнее